Equity Overview
Price & Market Data
Price: $1.02
Daily Change: +$0.01 / 0.98%
Range: $1.02 - $1.08
Market Cap: $881,063
Volume: 740
Performance Metrics
1 Week: -11.30%
1 Month: -17.74%
3 Months: -33.72%
6 Months: -39.29%
1 Year: -99.60%
YTD: -33.77%
Company Details
Employees: 23
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.